New Zealand
Include All CSL Sites



What is JESPECT®?

  • JESPECT® Japanese Encephalitis (JE) Virus, purified inactivated vaccine is a sterile, ready to use suspension for intramuscular (IM) injection. The vaccine is prepared by propagating Japanese encephalitis virus strain (SA14-14-2) in Vero cells. No preservatives or antibiotics are added to the formulation.
  • JESPECT® is a clear liquid with white precipitate and when shaken before use a white/cloudy suspension forms.
  • JESPECT® is supplied in pre-filled syringes without needles. Each 0.5ml dose of vaccine contains the following excipients: 0.1% aluminium hydroxide, hydrated corresponding to 0.25mg aluminium, and Phosphate Buffered Saline.

How it works

  • Animal studies in mice, rats and rabbits have shown that the JESPECT® vaccine induces the immune system to produce neutralizing antibodies against Japanese encephalitis virus which correlate with protection and survival. Mice treated with JESPECT® vaccine or human JESPECT® antisera demonstrated protection against lethal Japanese encephalitis challenge from several different (SA14, Beijing and KE-093) strains in a generally dose- or titre-dependent manner, respectively.

How much to take

  • Primary vaccination

    The primary vaccination series consists of a total of two doses of 0.5ml each according to the following schedule:

    First dose at Day 0 (elected date).

    Second dose at 28 days after first dose.

    It is recommended that persons who receive the first dose of JESPECT® complete the 2-dose primary vaccination course. If the primary immunization schedule of 2 doses is not completed, sufficient protection against Japanese encephalitis virus might not be achieved. Clinical trial data indicates that administration of the second dose up to 11 months after the first dose results in high seroconversion rates.
  • Booster dose

    Refer to Clinical Trials section in the data sheet (link below) for potential booster doses.

When to take it

The vaccine should be inspected visually for the particulate matter and discolouration prior to administration. Discard the product if particulates are present, if it appears discoloured or if the syringe appears to be physically damaged. Any unusual product or waste material should bedisposed of in accordance with local requirements.

JESPECT® should be well shaken before administration to obtain a homogenous suspension. Once shaken, the vaccine should appear as a white cloudy suspension.
JESPECT® should be administered by IM injection into the deltoid muscle. It should never be injected IV.

JESPECT® is an unfunded prescription medicine – a prescription charge will apply.
Description: 0.5 mL pre-filled needless syringe containing 6 micrograms of purified, inactivated Japanese Encephalitis (JE) virus. Indication: active immunisation against JE virus for persons 18 years of age and older. Contraindications: serious reaction and hypersensitivity to JESPECT. Precautions: primary vaccination(2 doses) should be completed at least one week prior to potential exposure; subcutaneous administration, acute severe febrile illness, flavivirus infection and/or vaccination against JE or Yellow fever, pregnancy(B1), lactation; immunosuppressive therapy, immunodeficiency. Adverse Effects: headache, myalgia; fatigue, influenza-like illness, nausea, pyrexia, rash, nasopharyngitis, injection site reactions, vomiting, diarrhoea; dyspnoea, increased hepatic enzymes, vertigo, palpitations, tachycardia, lymphadenitis, lymphadenopathy, thrombocytopaenia, paraesthesia, neuritis. Dosage and administration: Two 0.5 mL doses (intramuscular injections): first dose at day 0 and second dose 28 days after first dose. Storage conditions: Store in a refrigerator at 2° to 8°C. Do not freeze. Protect from light. Shake well before use. Before prescribing review JESPECT data sheet (dated Nov 2014) at or Seqirus (NZ) Ltd, Auckland, JESPECT is a registered trademark of Valneva Scotland Ltd.

JESP-006-02/17 TAPS MR5157

For further information, click on the helpful links below.


Helpful Links

Medicine Data Sheet
Consumer Medicine Information

Last Updated: 11-10-2018
© 2019 Seqirus